- Home
- /
- Drugs
- /
- A
- /
- Ammonium Lactate
- /
- Ammonium Lactate AMMONIUM LACTATE 12 g/100g Padagis Israel Pharmaceuticals Ltd
Ammonium Lactate
Summary of product characteristics
Adverse Reactions
ADVERSE REACTIONS The most frequent adverse experiences in patients with xerosis are transient stinging (1 in 30 patients), burning (1 in 30 patients), erythema (1 in 50 patients) and peeling (1 in 60 patients). Other adverse reactions which occur less frequently are irritation, eczema, petechiae, dryness, and hyperpigmentation. Due to the more severe initial skin conditions associated with ichthyosis, there was a higher incidence of transient stinging, burning and erythema (each occurring in 1 in 10 patients).
Contraindications
CONTRAINDICATIONS Ammonium Lactate Lotion, 12% is contraindicated in those patients with a history of hypersensitivity to any of the label ingredients.
Description
DESCRIPTION *Ammonium Lactate Lotion, 12% specially formulates 12% lactic acid neutralized with ammonium hydroxide, as ammonium lactate to provide a lotion pH of 4.5 - 5.5. It also contains cetyl alcohol, fragrance, glycerin, glyceryl stearate, laureth-4, light mineral oil, magnesium aluminum silicate, methylcellulose, methylparaben, PEG-100 stearate, polyoxyl 40 stearate, propylene glycol, propylparaben, and purified water. Lactic acid is a racemic mixture of 2-hydroxypropanoic acid and has the following structural formula: structural formula
Dosage And Administration
DOSAGE AND ADMINISTRATION Shake well. Apply to the affected areas and rub in thoroughly. Use twice daily or as directed by a physician.
Indications And Usage
INDICATIONS AND USAGE Ammonium Lactate Lotion, 12% is indicated for the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris, and for the temporary relief of itching associated with these conditions.
Warnings
WARNING Sun exposure (natural or artificial sunlight) to areas of the skin treated with Ammonium Lactate Lotion, 12% should be minimized or avoided (see PRECAUTIONS ). The use of Ammonium Lactate Lotion, 12% should be discontinued if any hypersensitivity is observed.
Overdosage
OVERDOSAGE The oral administration of ammonium lactate to rats and mice showed this drug to be practically non-toxic (LD 50 >15 mL/kg).
Clinical Pharmacology
CLINICAL PHARMACOLOGY Lactic acid is an alpha-hydroxy acid, it is a normal constituent of tissues and blood. The alpha-hydroxy acids (and their salts) may act as humectants when applied to the skin. This property may influence hydration of the stratum corneum. In addition, lactic acid, when applied to the skin, may act to decrease corneocyte cohesion. The mechanism(s) by which this is accomplished is not yet known. An in vitro study of percutaneous absorption of ammonium lactate lotion, 12% using human cadaver skin indicates that approximately 5.8% of the material was absorbed after 68 hours.
Effective Time
20220723
Version
9
Spl Product Data Elements
Ammonium Lactate Ammonium Lactate AMMONIUM LACTATE LACTIC ACID CETYL ALCOHOL GLYCERIN GLYCERYL MONOSTEARATE LAURETH-4 LIGHT MINERAL OIL MAGNESIUM ALUMINUM SILICATE METHYLCELLULOSE (400 MPA.S) METHYLPARABEN PEG-100 STEARATE POLYOXYL 40 STEARATE PROPYLENE GLYCOL PROPYLPARABEN WATER
Carcinogenesis And Mutagenesis And Impairment Of Fertility
Carcinogenesis, Mutagenesis, Impairment of Fertility - The topical treatment of CD-1 mice with 12%, 21% or 30% ammonium lactate formulations for two-years did not produce a significant increase in dermal or systemic tumors in the absence of increased exposure to ultraviolet radiation. The maximum systemic exposure of the mice in this study was 0.7 times the maximum possible systemic exposure in humans. However, a long-term photocarcinogenicity study in hairless albino mice suggested that topically applied 12% ammonium lactate formulations enhanced the rate of ultraviolet light-induced skin tumor formation. The mutagenic potential of ammonium lactate formulations was evaluated in the Ames assay and in the mouse in vivo micronucleus assay, both of which were negative. In dermal Segment I and III studies with ammonium lactate formulations there were no effects observed in fertility or pre- or postnatal development parameters in rats at dose levels of 300 mg/kg/day (1800 mg/m 2 /day), approximately 0.4 times the human topical dose.
Application Number
ANDA075570
Brand Name
Ammonium Lactate
Generic Name
Ammonium Lactate
Product Ndc
45802-419
Product Type
HUMAN PRESCRIPTION DRUG
Route
TOPICAL
Package Label Principal Display Panel
Principal Display Panel Rx Only NDC 45802- 419 -26 Ammonium Lactate Lotion, 12%* NET WT 400 g CONTAINS: *Ammonium lactate equivalent to 12% lactic acid, cetyl alcohol, fragrance, glycerin, glyceryl stearate, laureth-4, light mineral oil, magnesium aluminum silicate, methylcellulose, methylparaben, PEG-100 stearate, polyoxyl 40 stearate, propylene glycol, propylparaben, and purified water. Usual Dosage: Shake well. Apply to the affected areas and rub in thoroughly. Use twice daily or as directed by a physician. Keep out of reach of children. Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature]. For lot number and expiration date, see bottle. Manufactured By Padagis, Minneapolis, MN 55427 2204341 Rev 12-21 A 33PA7 RC F2 The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation. label serialization-template.jpg
Spl Unclassified Section
Rx Only For Dermatologic Use Only Not for Ophthalmic, Oral or Intravaginal Use
Information For Patients
Information for Patients Patients using Ammonium Lactate Lotion, 12% should receive the following information and instructions: 1. This medication is to be used as directed by the physician, and should not be used for any disorder other than for which it was prescribed. It is for external use only. Avoid contact with eyes, lips, or mucous membranes. 2. Patients should minimize or avoid use of this product on areas of the skin that may be exposed to natural or artificial sunlight, including the face. If sun exposure is unavoidable, clothing should be worn to protect the skin. 3. This medication may cause transient stinging or burning when applied to skin with fissures, erosions, or abrasions (for example, after shaving the legs). 4. If the skin condition worsens with treatment, the medication should be promptly discontinued.
Geriatric Use
Geriatric Use - Clinical studies of ammonium lactate lotion, 12% did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious.
Nursing Mothers
Nursing Mothers - Although lactic acid is a normal constituent of blood and tissues, it is not known to what extent this drug affects normal lactic acid levels in human milk. Because many drugs are excreted in human milk, caution should be exercised when ammonium lactate is administered to a nursing woman.
Pediatric Use
Pediatric Use - Safety and effectiveness of ammonium lactate have been demonstrated in infants and children. No unusual toxic effects were reported.
Pregnancy
Pregnancy: Teratogenic effects: Pregnancy Category B – Animal reproduction studies have been performed in rats and rabbits at doses up to 0.7 and 1.5 times the human dose, respectively (600 mg/kg/day, corresponding to 3600 mg/m 2 /day in the rat and 7200 mg/m 2 /day in the rabbit) and have revealed no evidence of impaired fertility or harm to the fetus due to ammonium lactate formulations. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Ammonium Lactate Lotion, 12% should be used during pregnancy only if clearly needed.
How Supplied
HOW SUPPLIED Ammonium Lactate Lotion, 12% is available as follows: 225 g bottle (NDC 45802- 419 -54) 400 g bottle (NDC 45802- 419 -26) STORAGE Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature].
Storage And Handling
STORAGE Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature].
General Precautions
General - For external use only. Stinging or burning may occur when applied to skin with fissures, erosions, or that is otherwise abraded (for example, after shaving the legs). Caution is advised when used on the face because of the potential for irritation. The potential for post-inflammatory hypo- or hyperpigmentation has not been studied.
Precautions
PRECAUTIONS General - For external use only. Stinging or burning may occur when applied to skin with fissures, erosions, or that is otherwise abraded (for example, after shaving the legs). Caution is advised when used on the face because of the potential for irritation. The potential for post-inflammatory hypo- or hyperpigmentation has not been studied. Information for Patients Patients using Ammonium Lactate Lotion, 12% should receive the following information and instructions: 1. This medication is to be used as directed by the physician, and should not be used for any disorder other than for which it was prescribed. It is for external use only. Avoid contact with eyes, lips, or mucous membranes. 2. Patients should minimize or avoid use of this product on areas of the skin that may be exposed to natural or artificial sunlight, including the face. If sun exposure is unavoidable, clothing should be worn to protect the skin. 3. This medication may cause transient stinging or burning when applied to skin with fissures, erosions, or abrasions (for example, after shaving the legs). 4. If the skin condition worsens with treatment, the medication should be promptly discontinued. Carcinogenesis, Mutagenesis, Impairment of Fertility - The topical treatment of CD-1 mice with 12%, 21% or 30% ammonium lactate formulations for two-years did not produce a significant increase in dermal or systemic tumors in the absence of increased exposure to ultraviolet radiation. The maximum systemic exposure of the mice in this study was 0.7 times the maximum possible systemic exposure in humans. However, a long-term photocarcinogenicity study in hairless albino mice suggested that topically applied 12% ammonium lactate formulations enhanced the rate of ultraviolet light-induced skin tumor formation. The mutagenic potential of ammonium lactate formulations was evaluated in the Ames assay and in the mouse in vivo micronucleus assay, both of which were negative. In dermal Segment I and III studies with ammonium lactate formulations there were no effects observed in fertility or pre- or postnatal development parameters in rats at dose levels of 300 mg/kg/day (1800 mg/m 2 /day), approximately 0.4 times the human topical dose. Pregnancy: Teratogenic effects: Pregnancy Category B – Animal reproduction studies have been performed in rats and rabbits at doses up to 0.7 and 1.5 times the human dose, respectively (600 mg/kg/day, corresponding to 3600 mg/m 2 /day in the rat and 7200 mg/m 2 /day in the rabbit) and have revealed no evidence of impaired fertility or harm to the fetus due to ammonium lactate formulations. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Ammonium Lactate Lotion, 12% should be used during pregnancy only if clearly needed. Nursing Mothers - Although lactic acid is a normal constituent of blood and tissues, it is not known to what extent this drug affects normal lactic acid levels in human milk. Because many drugs are excreted in human milk, caution should be exercised when ammonium lactate is administered to a nursing woman. Pediatric Use - Safety and effectiveness of ammonium lactate have been demonstrated in infants and children. No unusual toxic effects were reported. Geriatric Use - Clinical studies of ammonium lactate lotion, 12% did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
Disclaimer
The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).
Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.
Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.